|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Massachusetts Eye and Ear Infirmary |
|---|---|
| Information provided by: | Massachusetts Eye and Ear Infirmary |
| ClinicalTrials.gov Identifier: | NCT00559936 |
Purpose
The purpose of this study is to determine the effectiveness and safety of Topical Bevacizumab (Avastin) for treatment of corneal neovascularization.
| Condition | Intervention | Phase |
|---|---|---|
|
Corneal Neovascularization |
Drug: Topical Bevacizumab |
Phase I |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Effectiveness and Safety of Topical Bevacizumab (Avastin) for Treatment of Corneal Neovascularization |
| Estimated Enrollment: | 20 |
| Study Start Date: | February 2007 |
| Study Completion Date: | October 2010 |
| Primary Completion Date: | October 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: I
Each patient will receive topical Avastin in one eye.
|
Drug: Topical Bevacizumab
1.0% custom made topical Avastin twice a day for three weeks
|
Eligibility| Ages Eligible for Study: | 18 Years to 75 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| United States, Massachusetts | |
| Massachusetts Eye and Ear Infirmary | |
| Boston, Massachusetts, United States, 02114 | |
| Principal Investigator: | Reza Dana, M.D., MPH | Massachusetts Eye and Ear Infirmary |
More Information
| Responsible Party: | Reza Dana, Principal Investigator, Massachusetts Eye & Ear Infirmary |
| ClinicalTrials.gov Identifier: | NCT00559936 History of Changes |
| Other Study ID Numbers: | 06-12-077, 06-12-077 |
| Study First Received: | November 14, 2007 |
| Last Updated: | December 2, 2010 |
| Health Authority: | United States: Institutional Review Board |
|
Neovascularization, Pathologic Corneal Neovascularization Metaplasia Pathologic Processes Corneal Diseases Eye Diseases Bevacizumab Angiogenesis Inhibitors |
Angiogenesis Modulating Agents Growth Substances Physiological Effects of Drugs Pharmacologic Actions Growth Inhibitors Antineoplastic Agents Therapeutic Uses |